Y-Intercept (HK)’s Sutro Biopharma STRO Stock Holding History

Y-Intercept (HK)’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.46M	Buy	90,536 +34,657	+62%	+$765K	0.03%	793
2026 Q2	$1.86M	Buy	+55,879	New	+$1.74M	0.04%	746
2025 Q3	–	Sell	-6,659	Closed	-$47.5K	–	2027
2025 Q2	$47.5K	Buy	+6,659	New	+$54.5K	﹤0.01%	1561
2023 Q3	–	Sell	-1,419	Closed	-$66K	–	1567
2023 Q2	$66K	Buy	+1,419	New	+$70.6K	0.01%	1174

Other funds holding STRO

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Y-Intercept (HK)'s STRO Position: Q3 2026 in Review

Y-Intercept (HK) increased its Sutro Biopharma (STRO) stake by 62% in Q3 2026, buying an estimated $765K and bringing the position to 90,536 shares worth $1.46M. The position accounts for 0.03% of the portfolio, ranked #793.

Y-Intercept (HK) first reported a position in STRO in Q2 2023 and has held it in 4 quarters since. The position peaked at $1.86M in Q2 2026. 9 funds tracked by Wall St. Rank hold STRO as of Q3 2026.

Y-Intercept (HK) held 90,536 shares of Sutro Biopharma worth $1.46M as of Q3 2026.
Y-Intercept (HK) bought 34,657 Sutro Biopharma shares in Q3 2026, an estimated $765K.
Sutro Biopharma made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #793 holding.
Y-Intercept (HK) first reported a position in Sutro Biopharma in Q2 2023 and has held it in 4 quarters since.
Y-Intercept (HK)'s Sutro Biopharma position peaked at $1.86M in Q2 2026.
9 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.